Jazz Pharmaceuticals plc (J7Z) — Cash Flow Quality Index
Jazz Pharmaceuticals plc (J7Z) has a Cash Flow Quality Index of 1.39x as of March 2026. Operating cash flow of €408.20 Million exceeds net income of €293.10 Million, indicating high earnings quality where cash backs reported profits. Explore long-term investment intensity of Jazz Pharmaceuticals plc to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Jazz Pharmaceuticals plc Cash Flow Quality Index (2013–2024)
Historical Cash Flow Quality Index for Jazz Pharmaceuticals plc across 10 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Jazz Pharmaceuticals plc tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Jazz Pharmaceuticals plc (2013–2024)
Year-by-year earnings quality comparison for Jazz Pharmaceuticals plc. For live market cap and the full company financial profile, see J7Z market cap.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 2.49x | €1.40 Billion | €560.12 Million | ▼ -5.3% |
| 2023 | 2.63x | €1.09 Billion | €414.83 Million | ▼ -30.2% |
| 2020 | 3.77x | €899.65 Million | €238.62 Million | ▲ +154.2% |
| 2019 | 1.48x | €776.40 Million | €523.37 Million | ▼ -17.0% |
| 2018 | 1.79x | €798.90 Million | €447.10 Million | ▲ +25.8% |
| 2017 | 1.42x | €693.09 Million | €487.85 Million | ▼ -4.8% |
| 2016 | 1.49x | €592.39 Million | €396.83 Million | ▼ -7.5% |
| 2015 | 1.61x | €531.94 Million | €329.54 Million | ▼ -76.9% |
| 2014 | 6.98x | €407.61 Million | €58.39 Million | ▲ +423.6% |
| 2013 | 1.33x | €288.43 Million | €216.31 Million | — |